MIN-117: Phase IIa data

Top-line data from a double-blind, European Phase IIa trial in 84 patients with moderate to severe MDD showed that once-daily 0.5 and

Read the full 222 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE